APTA vs. POLB, OKYO, SAR, SNG, AOR, AREC, IMM, OPTI, RLM, and NSCI
Should you be buying Aptamer Group stock or one of its competitors? The main competitors of Aptamer Group include Poolbeg Pharma (POLB), OKYO Pharma (OKYO), Sareum (SAR), Synairgen (SNG), AorTech International (AOR), Arecor Therapeutics (AREC), ImmuPharma (IMM), OptiBiotix Health (OPTI), Realm Therapeutics (RLM), and NetScientific (NSCI). These companies are all part of the "biotechnology" industry.
Aptamer Group vs.
Poolbeg Pharma (LON:POLB) and Aptamer Group (LON:APTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, community ranking, institutional ownership, risk and dividends.
In the previous week, Poolbeg Pharma had 1 more articles in the media than Aptamer Group. MarketBeat recorded 1 mentions for Poolbeg Pharma and 0 mentions for Aptamer Group. Poolbeg Pharma's average media sentiment score of 0.30 beat Aptamer Group's score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the media.
Poolbeg Pharma and Aptamer Group both received 0 outperform votes by MarketBeat users.
Aptamer Group has higher revenue and earnings than Poolbeg Pharma. Aptamer Group is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.
Poolbeg Pharma has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, Aptamer Group has a beta of -0.52, indicating that its share price is 152% less volatile than the S&P 500.
1.2% of Poolbeg Pharma shares are held by institutional investors. Comparatively, 11.7% of Aptamer Group shares are held by institutional investors. 24.7% of Poolbeg Pharma shares are held by insiders. Comparatively, 13.2% of Aptamer Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Poolbeg Pharma has a net margin of 0.00% compared to Aptamer Group's net margin of -343.95%. Poolbeg Pharma's return on equity of -32.56% beat Aptamer Group's return on equity.
Summary
Poolbeg Pharma beats Aptamer Group on 8 of the 12 factors compared between the two stocks.
Get Aptamer Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for APTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptamer Group Competitors List
Related Companies and Tools
This page (LON:APTA) was last updated on 2/22/2025 by MarketBeat.com Staff
